June 6, 2022 12:18 PM EDT

FDA shines light on Indian manufacturer’s misgivings at one of its facilities

Tyler Patchen

News Reporter

Last month, Indian drug manufacturer Aurobindo Pharma let the national stock exchange know that they once again invoked the ire of US regulators. Now …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA shines light on Indian manufacturer’s misgivings at one of its facilities

Tyler Patchen

News Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA approves Dupixent for hives, rejects new Eylea dosing schedule

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

FDA shines light on In­di­an man­u­fac­tur­er’s mis­giv­ings at one of its fa­cil­i­ties

News Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA shines light on Indian manufacturer’s misgivings at one of its facilities